Kathleen Digre is a Neurology physician affiliated with Utah Department of Health. OpenAlex indexes 397 publications with 11,379 citations (h-index 57); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
65 N Medical Dr
Salt Lake City, UT 841321000
Telephone
801-581-2352Provider last certified this registry record 20 Oct 2021.
Clinical trials
- Coalition for a Healthier Community-Utah Women and Girls - Phase II (UWAG-II)
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Baxter HealthcareProgram year20245 payments$15,564openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
89.2%Calcitonin gene-related peptide (CGRP) antagonists31.8%Aimovig Autoinjector64%Emgality Pen36%Part D<11 patientsSerotonin-1b and Serotonin-1d Receptor Agonist21.6%Sumatriptan Succinate45%Rizatriptan35%Naratriptan Hcl20%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
4.3%Serotonin-3 Receptor Antagonist4.3%Ondansetron Hcl100%Part D<11 patientsSensory organs
3.2%Carbonic Anhydrase Inhibitor3.2%Acetazolamide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1992–1997 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
Headache The Journal of Head and Face Pain
2024 - Young Adults With Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study
American Journal of Ophthalmology
2020 - Utility of Magnetic Resonance Imaging Features for Improving the Diagnosis of Idiopathic Intracranial Hypertension Without Papilledema
Journal of Neuro-Ophthalmology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”